Tjitra E, Suprianto S, Currie B J, Morris P S, Saunders J R, Anstey N M
National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia.
Am J Trop Med Hyg. 2001 Oct;65(4):309-17. doi: 10.4269/ajtmh.2001.65.309.
Combining artesunate with existing antimalarial drugs may improve cure rates, delay emergence of resistance, and reduce transmission. We performed a randomized comparative trial to quantify the effect of adding artesunate to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in Indonesia. Using a modified 1997 World Health Organization protocol for assessment of therapeutic efficacy of antimalarial drugs, 105 patients (stratified by age/ethnic group) were randomized: 53 received artesunate orally, 4 mg/kg of body weight, a single daily dose for three days, plus sulfadoxine-pyrimethamine orally (1.25 mg of pyrimethamine/kg of body weight), a single dose on day 0, and 52 patients received sulfadoxine-pyrimethamine alone. Six from the combination group were withdrawn from analysis, as were six of the sulfadoxine-pyrimethamine group. Treatment failure rates on day 14 were 0% in the artesunate plus sulfadoxine-pyrimethamine group and 8.7% in the sulfadoxine-pyrimethamine group (P = 0.12). Treatment failure rates on day 28 were 4.4% and 15.2%, respectively (P = 0.16). Relative risk of treatment failure at 28 days was 0.3 (95% confidence interval [CI] = 0.1-1.3). Mean fever clearance time (1.3 versus 1.7 days) and mean parasite clearance time (1.4 versus 2.0 days) were both faster in the artesunate plus sulfadoxine-pyrimethamine group than in the sulfadoxine-pyrimethamine group (P = 0.08 and P < 0.0001, respectively). Only 20 (39.2%) of 51 patients treated with artesunate plus sulfadoxine-pyrimethamine were still parasitemic on day 1 compared with 45 (86.5%) of 52 patients treated with sulfadoxine-pyrimethamine alone (P = 0.000001, relative risk [RR] = 0.4, 95% CI = 0.3-0.6). Gametocyte carriage was lower following artesunate plus sulfadoxine-pyrimethamine than following sulfadoxine-pyrimethamine (RR = 0.5, 95% CI = 0.2-1.0 on day 7 and RR = 0.5, 95% CI = 0.2-1.1 on day 14). Mild diarrhea, rash, and itching resolved without treatment. Combined artesunate plus sulfadoxine-pyrimethamine resulted in more rapid fever and parasiteclearance, was well tolerated, reduced risk of treatment failure, and lowered gametocyte carriage.
将青蒿琥酯与现有抗疟药物联合使用可能会提高治愈率、延缓耐药性的出现并减少传播。我们进行了一项随机对照试验,以量化在印度尼西亚治疗非复杂性恶性疟时,在磺胺多辛-乙胺嘧啶中添加青蒿琥酯的效果。采用1997年世界卫生组织修订的抗疟药物治疗效果评估方案,105例患者(按年龄/种族分组)被随机分组:53例口服青蒿琥酯,4毫克/千克体重,每日单次剂量,连用三天,加口服磺胺多辛-乙胺嘧啶(1.25毫克乙胺嘧啶/千克体重),第0天单次给药;52例患者仅接受磺胺多辛-乙胺嘧啶治疗。联合治疗组有6例退出分析,磺胺多辛-乙胺嘧啶组也有6例退出分析。青蒿琥酯加磺胺多辛-乙胺嘧啶组第14天的治疗失败率为0%,磺胺多辛-乙胺嘧啶组为8.7%(P = 0.12)。第28天的治疗失败率分别为4.4%和15.2%(P = 0.16)。28天时治疗失败的相对风险为0.3(95%置信区间[CI] = 0.1 - 1.3)。青蒿琥酯加磺胺多辛-乙胺嘧啶组的平均退热时间(1.3天对1.7天)和平均原虫清除时间(1.4天对2.0天)均比磺胺多辛-乙胺嘧啶组更快(分别为P = 0.08和P < 0.0001)。与仅接受磺胺多辛-乙胺嘧啶治疗的52例患者中的45例(86.5%)相比,接受青蒿琥酯加磺胺多辛-乙胺嘧啶治疗的51例患者中仅20例(39.2%)在第1天仍有寄生虫血症(P = 0.000001,相对风险[RR] = 0.4,95% CI = 0.3 - 0.6)。青蒿琥酯加磺胺多辛-乙胺嘧啶治疗后配子体携带率低于磺胺多辛-乙胺嘧啶治疗(第7天RR = 0.5,95% CI = 0.2 - 1.0;第14天RR = 0.5,95% CI = 0.2 - 1.1)。轻度腹泻、皮疹和瘙痒未经治疗即缓解。青蒿琥酯与磺胺多辛-乙胺嘧啶联合使用可使发热和原虫清除更快,耐受性良好,降低治疗失败风险,并降低配子体携带率。